1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Diagnostic Imaging Market Trends
Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

  • May 2020
  • 380 pages
  • ID: 5891712
  • Format: PDF
  • Renub Research

Summary

Table of Contents

Breast Cancer Screening Market, Global Forecast by Screening Test, Population, Countries, Company Analysis

Globally, breast cancer is considered one of the most common cancers in women around the world.
Breast cancer is also a leading cause of death from cancer in the world’s least developed nations. Every year 1.7 Million new cases are diagnosed with breast cancer, and approximately 60% of deaths due to breast cancer occur around the world. Breast cancer is a form of cancer that occurs in the tissue of the breast. Formations of a lump in a breast and red patches on the skin are some of the typical breast cancer signs. Obesity, lack of physical activity, overexposure to radiation, and consuming alcohol are among the risk factors for breast cancer growth. According to the research report, the Global Breast Cancer Screening Market is anticipated to reach US$ 51.8 Billion by the end of the year 2026, with double-digit CAGR during the forecast period.

COVID – 19 impact on Breast Cancer Screening Market Worldwide
The COVID-19 outbreak could have an impact on all drug companies manufacturing, supply chain, and clinical trial operations. In the year 2020, the global breast cancer screening population, as well as the market, will decline. The primary reason for this decline is a coronavirus. For a complete analysis, read our report as to how COVID – 19 is affecting every quarter of the year 2020 and when the market will revive? Other challenges of breast cancer screening are high medication costs, therapy-related adverse effects, and lengthy product approval times are responsible for curbing market growth.

Growth Factors for Global Breast Cancer Screening Market
The key growth factors of the breast cancer market are the increasing number of females suffering from breast cancer, growing older women population is the primary factor for the growth of the market. In addition to this adoption of an unhealthy lifestyle, the rise of the female geriatric population, exposure to harmful radiation, and increased policy measures have contributed to market growth.

Also, the incidence of breast cancer is rising in the lower-income countries due to an increase in life expectancy, adaption to increasing urbanization and western lifestyles. World over, more than half of the breast cancer cases now have been reported from low and middle-income countries (LMICs) as these countries do not have proper breast screening programs; hence, the majority of cases are diagnosed in late stages. Growing breast cancer incidences & mortality in the low and middle-income countries, these countries need to develop an effective breast cancer screening program strategy that will address the earlier deduction of incidence of breast cancer for women.

Some of the major breast cancer screening technologies which help to find breast cancer after diagnosis are as follows. Breast cancer screening technologies are MRI, Ultrasound, and mammography screening. Mammography screening aims at minimizing the death rate from breast cancer by identifying unsuspected breast cancers early. The breast cancer mammography screening market is flourishing, driven by advances in technologies and delivery models, product innovations, increasing use of digital mammography equipment, and growing public awareness. Globally, awareness about breast cancer is increasing, with more women coming forward for their yearly mammograms after the age of 40 years.

Besides, around the world, governments have introduced screening programs for early detection that entails a routine check-up. Several countries are already offering breast cancer screening programs for women, and the number is establishing these programs are steadily increasing. In Germany, for example, the “Mammo Screening” program exists since 2002. In the United States, most states are introducing laws requiring health insurance companies to reimburse all or part of the cost of screening mammograms. Furthermore, the NHS Breast Screening Program in the United Kingdom provides free breast screening every three years for all women aged. Also, continuous efforts are taken by various government agencies and NGOs, the worldwide market for breast cancer screening.

This latest study report “Breast Cancer Screening Market, Population, By Screening Tests [Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound] Countries (United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, Saudi Arabia), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG)” provides a detailed and comprehensive insight of the Breast Cancer Screening Market.

Screening Tests - Mammography is the Most Common Test for Breast Cancer Screening
Mammography is sophisticated medical imaging that uses a low-dose x-ray device to view human breasts indoors. Mammography plays a vital role in the early detection and treatment of women with breast diseases. Breast Magnetic Resonance Imaging (MRI) or breast ultrasound, in addition to mammography, also helps detect breast cancer in women.

Countries – Total 23 Countries Market & Population for Breast Cancer Screening, Mammography Screening, MRI Screening & Ultrasound Screening has been studied in the report

The study includes a comprehensive Breast cancer overview of Canada, France, Italy, Spain, Switzerland, Netherlands, Norway, India, Australia, Japan, Korea, Singapore, Thailand, Malaysia, Brazil, New Zealand, South Africa, United Arab Emirates and Saudi Arabia Breast Cancer, Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population and Market.

The report provides a complete analysis of the key Growth Drivers, Challenges, Market, Screened Population, and their projections for the upcoming years till 2026.

All the companies have been studied from two points
• Recent Developments
• Sales Analysis

Company Analysis
• AstraZeneca
• Novartis
• Sanofi
• Pfizer
• Bayer AG

Breast Cancer Screening Market & Population - By Screening Tests Covered in the Report
• Mammography
• Magnetic Resonance Imaging (MRI)
• Ultrasound

23 Regions Covered in the Report:

1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Netherlands
9. Norway
10. Switzerland
11. India
12. China
13. Japan
14. Korea
15. Singapore
16. Thailand
17. Malaysia
18. Brazil
19. Australia
20. New Zealand
21. South Africa
22. United Arab Emirates
23. Saudi Arabia

Globally, breast cancer is considered one of the most common cancers in women around the world. Breast cancer is also a leading cause of death from cancer in the world’s least developed nations. Every year 1.7 Million new cases are diagnosed with breast cancer, and approximately 60% of deaths due to breast cancer occur around the world. Breast cancer is a form of cancer that occurs in the tissue of the breast. Formations of a lump in a breast and red patches on the skin are some of the typical breast cancer signs. Obesity, lack of physical activity, overexposure to radiation, and consuming alcohol are among the risk factors for breast cancer growth. According to the research report, the Global Breast Cancer Screening Market is anticipated to reach US$ 51.8 Billion by the end of the year 2026, with double-digit CAGR during the forecast period.

COVID – 19 impact on Breast Cancer Screening Market Worldwide
The COVID-19 outbreak could have an impact on all drug companies manufacturing, supply chain, and clinical trial operations. In the year 2020, the global breast cancer screening population, as well as the market, will decline. The primary reason for this decline is a coronavirus. For a complete analysis, read our report as to how COVID – 19 is affecting every quarter of the year 2020 and when the market will revive? Other challenges of breast cancer screening are high medication costs, therapy-related adverse effects, and lengthy product approval times are responsible for curbing market growth.

Growth Factors for Global Breast Cancer Screening Market
The key growth factors of the breast cancer market are the increasing number of females suffering from breast cancer, growing older women population is the primary factor for the growth of the market. In addition to this adoption of an unhealthy lifestyle, the rise of the female geriatric population, exposure to harmful radiation, and increased policy measures have contributed to market growth.

Also, the incidence of breast cancer is rising in the lower-income countries due to an increase in life expectancy, adaption to increasing urbanization and western lifestyles. World over, more than half of the breast cancer cases now have been reported from low and middle-income countries (LMICs) as these countries do not have proper breast screening programs; hence, the majority of cases are diagnosed in late stages. Growing breast cancer incidences & mortality in the low and middle-income countries, these countries need to develop an effective breast cancer screening program strategy that will address the earlier deduction of incidence of breast cancer for women.

Some of the major breast cancer screening technologies which help to find breast cancer after diagnosis are as follows. Breast cancer screening technologies are MRI, Ultrasound, and mammography screening. Mammography screening aims at minimizing the death rate from breast cancer by identifying unsuspected breast cancers early. The breast cancer mammography screening market is flourishing, driven by advances in technologies and delivery models, product innovations, increasing use of digital mammography equipment, and growing public awareness. Globally, awareness about breast cancer is increasing, with more women coming forward for their yearly mammograms after the age of 40 years.

Besides, around the world, governments have introduced screening programs for early detection that entails a routine check-up. Several countries are already offering breast cancer screening programs for women, and the number is establishing these programs are steadily increasing. In Germany, for example, the “Mammo Screening” program exists since 2002. In the United States, most states are introducing laws requiring health insurance companies to reimburse all or part of the cost of screening mammograms. Furthermore, the NHS Breast Screening Program in the United Kingdom provides free breast screening every three years for all women aged. Also, continuous efforts are taken by various government agencies and NGOs, the worldwide market for breast cancer screening.

This latest study report “Breast Cancer Screening Market, Population, By Screening Tests [Mammography, Magnetic Resonance Imaging (MRI) & Ultrasound] Countries (United States, Canada, France, United Kingdom, Germany, Italy, Spain, Netherlands, Norway, Switzerland, China, India, Korea, Japan, Singapore, Thailand, Malaysia, Brazil, Australia, New Zealand, South Africa, United Arab Emirates, Saudi Arabia), Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG)” provides a detailed and comprehensive insight of the Breast Cancer Screening Market.

Screening Tests - Mammography is the Most Common Test for Breast Cancer Screening
Mammography is sophisticated medical imaging that uses a low-dose x-ray device to view human breasts indoors. Mammography plays a vital role in the early detection and treatment of women with breast diseases. Breast Magnetic Resonance Imaging (MRI) or breast ultrasound, in addition to mammography, also helps detect breast cancer in women.

Countries – Total 23 Countries Market & Population for Breast Cancer Screening, Mammography Screening, MRI Screening & Ultrasound Screening has been studied in the report

The study includes a comprehensive Breast cancer overview of Canada, France, Italy, Spain, Switzerland, Netherlands, Norway, India, Australia, Japan, Korea, Singapore, Thailand, Malaysia, Brazil, New Zealand, South Africa, United Arab Emirates and Saudi Arabia Breast Cancer, Mammography, Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population and Market.

The report provides a complete analysis of the key Growth Drivers, Challenges, Market, Screened Population, and their projections for the upcoming years till 2026.

All the companies have been studied from two points
• Recent Developments
• Sales Analysis

Company Analysis
• AstraZeneca
• Novartis
• Sanofi
• Pfizer
• Bayer AG

Breast Cancer Screening Market & Population - By Screening Tests Covered in the Report
• Mammography
• Magnetic Resonance Imaging (MRI)
• Ultrasound

23 Regions Covered in the Report:

1. United States
2. Canada
3. United Kingdom
4. France
5. Germany
6. Italy
7. Spain
8. Netherlands
9. Norway
10. Switzerland
11. India
12. China
13. Japan
14. Korea
15. Singapore
16. Thailand
17. Malaysia
18. Brazil
19. Australia
20. New Zealand
21. South Africa
22. United Arab Emirates
23. Saudi Arabia

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on